Led · Seed · Jun 2026

Cardiovolt.ai developed the AI-ECG Risk Estimation (AIRE) platform to extract signals from standard ECGs that are not visible to human clinicians. The platform has been validated across about 6 million ECGs spanning four continents and the work has been published in The Lancet Digital Health, European Heart Journal, and JAMA Cardiology. The technology traces its origins to research conducted in Fu Siong Ng's lab at the National Heart and Lung Institute, Imperial College. The company says it is moving from research into clinical reality and recently raised a £1.44M pre-seed round to provide runway for that transition. Supporters and partners named in the fundraising announcement include Twin Path Ventures, Innovate UK, Imperial Enterprise Lab, Future Worlds, AI SuperConnector, and the London Institute for Healthcare Engineering. The team emphasizes the scientific foundation and peer-reviewed validation as central to its development and go-to-clinic plans.

Participated · Series A · May 2026

Recursive Superintelligence is a newly formed company focused on self-teaching AI. Press coverage notes the company is only months old. Public reporting links the company to a single disclosed financing event in which it raised $500 million. The articles do not provide metrics such as revenue, users, or customers, nor do they outline specific product features or roadmaps. Beyond its characterization as a self-teaching AI startup and the reported financing, no further operational or financial details were disclosed in the cited coverage.

Led · Seed · Apr 2026

WholeSum offers an API-first hybrid AI and statistical inference platform designed to convert large volumes of unstructured text into uncertainty-aware, reproducible, and auditable insights. The company targets high-trust, regulated sectors such as pharmaceuticals, financial services, healthcare, and defence where reproducibility and methodological rigour are critical. Founded by Emily Kucharski and Dr Adam Kucharski, WholeSum has seen early traction with pilots and enterprise integrations across universities, financial institutions, and pharmaceutical companies. Financially, the startup has brought its total Pre-Seed funding to $1.3 million after the recent $335,000 top-up, which follows an earlier $965,000 raise led by Twin Path Ventures. The company plans to use funds to accelerate R&D, hire scientific and engineering talent, and scale deployments for increasingly complex, large-scale datasets.

Led · Seed · Mar 2026

TileBio has created a self-learning AI platform that ingests millions of unlabelled whole-slide pathology images and extracts clinically relevant patterns without the need for manual annotation. By leveraging large-scale real-world data from NHS Greater Glasgow and Clyde, the system aims to generalise across cancer types, detect disease earlier, and uncover novel biomarkers useful for drug development. The company’s technology hinges on foundation-model-style representation learning, which promises faster, more accurate, and more interpretable results than traditional medical AI approaches that rely on expensive ground-truth labels. Near-term plans include large-scale model training, extensive clinical validation studies, and the recruitment of deep-learning engineers, data managers, regulatory specialists, and commercial leads. Longer term, TileBio intends to build one of the world’s largest pathology foundation models spanning more than two million whole-slide images and to deploy it population-wide for cancer triage. Financially, the company has raised £1.6 million in seed capital, providing runway to hit key technical and regulatory milestones. No revenue or user metrics have yet been disclosed.

Participated · Equity · Jan 2026

Shield Space is a 2025-founded defence technology startup focused on safeguarding satellites from signal jamming, direct attacks, and other counter-space threats. Its core product is an autonomous, AI-powered guidance platform that allows spacecraft to identify hazards in real time and execute evasive manoeuvres independently, overcoming the latency of ground-based control. The company positions this capability as critical national infrastructure support for the UK, NATO and allied forces operating in increasingly contested orbits. With its technology nearing flight-ready status, Shield Space is preparing for its first orbital test mission to validate performance in space. Proceeds from its recent funding will also finance new premises in Lincoln and an expanded technical team to accelerate product maturation. Although the business has not disclosed revenue or user metrics, it is currently pre-deployment and focused on R&D and flight demonstrations.